---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-045028"
form_type: "8-K"
ticker: "AQST"
cik: "0001398733"
company_name: "Aquestive Therapeutics, Inc."
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T05:54:58.123394+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aquestive Q3 net loss $11.5M vs $2.0M; revenue up 4% to $13.5M; Anaphylm pre-NDA meeting in Q4

## Summary
- Total revenues $13.5M (+4% YoY); net loss $11.5M ($0.13/sh) vs $2.0M loss in Q3 2023.
- Cash $77.9M; FY2024 guidance: revenue $57-60M, adj EBITDA loss $20-23M.
- Anaphylm pre-NDA meeting with FDA scheduled Q4 2024; NDA submission targeted Q1 2025, launch Q1 2026 if approved.
- AQST-108 (epinephrine topical gel) pre-IND meeting Q4 2024; Phase 2a in alopecia areata planned Q2 2025.
- Libervant launched for ages 2-5 with dedicated sales force; commercial and Medicaid coverage expanded nationwide.

## SEC filing metadata
- accession: 0001628280-24-045028
- form_type: 8-K
- ticker: AQST
- cik: 0001398733
- company_name: Aquestive Therapeutics, Inc.
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1398733/000162828024045028/0001628280-24-045028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1398733/000162828024045028/aqst-20241104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-045028
- JSON: https://secwatch.observer/filing/0001628280-24-045028.json
- Plain text: https://secwatch.observer/filing/0001628280-24-045028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.